daunorubicin

Daunorubicin是一种具有抗癌活性的蒽环类抗生素和topoisomerase II抑制剂，能够抑制DNA和RNA的合成，常用于治疗急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）。

Daunorubicin hydrochloride (Rubidomycin hydrochloride) 是一种蒽环类氨基糖苷类化合物，一种拓扑异构酶 II (Topo II) 抑制剂。Daunorubicin hydrochloride 可以抑制 DNA 和 RNA 的合成，具有抗肿瘤活性。

Daunosamnyl-daunorubicin is used as an antibody conjugate.

Alanylleucyl-daunorubicin is a biochemical.

Daunorubicin citrate（Daunomycin citrate）作为一种拓扑异构酶 II（topoisomerase II）抑制剂，展现出有效的抗肿瘤活性，通过抑制 DNA 和 RNA 合成（DNA and RNA synthesis）发挥作用。作为一种细胞毒性药物，Daunorubicin citrate 能够抑制癌细胞活性，并诱导细胞凋亡（apoptosis）和坏死（necrosis），属于蒽环类抗生素范畴。该化合物广泛应用于包括白血病、非霍奇金淋巴瘤、尤文氏肉瘤、维尔姆斯氏瘤在内的多种癌症和感染研究领域。

N-Trifluoroacetamido-4′-p-nitrobenzoyl daunorubicin 一种在生化反应中使用的试剂。

Daunorubicinol, a potent antitumor drug-linker conjugate for antibody-drug conjugate (ADC) applications, utilizes Aur0101 (DNA Topoisomerase II inhibitor) connected through the ADC linker[1].

Daunorubicinol is the main metabolite of daunomycin.

5-Iminodaunorubicin hydrochloride 是一种醌改性蒽环类药物，具有抗肿瘤活性。5-Iminodaunorubicin hydrochloride 在癌细胞中可诱导DNA 链断裂。

5-Iminodaunorubicin 是一种醌改性蒽环类药物，具有抗肿瘤活性。5-Iminodaunorubicin 在癌细胞中可诱导 DNA 链断裂。

Doxorubicin hydrochloride 是一种具有细胞毒性和抗肿瘤活性的蒽环类抗生素，是人类DNA拓扑异构酶I和II的有效抑制剂，IC50分别为0.8 μM和2.67 μM。它不仅能够降低AMPK及其下游靶蛋白乙酰辅酶A羧化酶的磷酸化，还可诱导细胞发生凋亡和自噬。在动物实验中，Doxorubicin hydrochloride 常被用于诱导急性肾衰竭、慢性肾损伤以及心力衰竭模型。

Aldoxorubicin has effective antitumor activities in various cancer cell lines and in murine tumor models. Aldoxorubicin is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitors).

Doxorubicin（Adriamycin）是一种具有荧光性的蒽环类抗肿瘤抗生素，可抑制Topoisomerase I II，诱导细胞凋亡和自噬，下调AMPK信号通路，常用于肿瘤化疗，并可用于诱导肾炎和心力衰竭模型。

Idarubicin hydrochloride (Zavedos) 是一种蒽环类抗白血病药物，能抑制细菌和酵母菌生长，还抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。

Daun02 is the topoisomerase inhibitor Daunorubicin prodrug.

PNU-159682 是蒽环类新霉素的代谢产物，是一种 DNA 拓扑异构酶 II 抑制剂，具有出色的细胞毒性。

Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.

Feudomycin A(封建霉素 A)是一种由突变链霉菌产生的蒽环类抗生素，在特定微生物作用下可以转化为adriamycin，具有潜在的抗肿瘤活性。

1,4-Anthraquinone 是一种抗癌药物，在体外与柔红霉素相同纳摩尔范围内阻断核苷转运、抑制大分子合成、诱导 DNA 片段化并降低 L1210 白血病细胞的生长和活力。它被提议为一种用于高效液相色谱 (HPLC) 测定药物制剂中 N-乙酰半胱氨酸 (NAC) 和卡托普利 (CAP) 的新型柱前试剂。

Ruboxyl, a nitroxylated analog of daunorubicin, is an anthracycline antibiotic.

Dihydrodaunomycin HCl is a metabolite of Daunorubicin.

Olomoucine II is an inhibitor of cyclin-dependent kinases (CDKs; IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 μM for Cdk1, -2, -4, -7, and -9, respectively).1It is selective for CDKs over 10 additional kinases (IC50s = >100 μM for all) but does inhibit ERK2 (IC50= 32 μM) and the ATP-binding cassette transporter B1 (ABCB1; IC50= 6.4 μM).1,2Olomoucine II inhibits proliferation of a variety of cancer cells, including those expressing wild-type p53 or mutant p53 (mean IC50s = 7.4 and 10.1 μM, respectively), and it acts synergistically with daunorubicin to inhibit proliferation of HCT-8 cells that endogenously express ABCB1. Olomoucine also inhibits replication of herpes simplex virus 1 (HSV-1), HSV-2, vaccinia virus, human adenovirus type 4 (Ad4), and human CMV (IC50s = 5, 4.7, 3.8, 2.4, and 3.2 μM, respectively) but not measles virus or influenza virus (IC50s = >20 μM for both).3

NR-160 is an inhibitor of histone deacetylase 6 (HDAC6; IC50= 0.03 μM).1It is selective for HDAC6 over HDAC1, -2, -3, -4, and -8 (IC50s = 5.18, 2.26, 8.48, 55.4, and 14.7 μM, respectively). NR-160 is cytotoxic against a panel of seven cancer cell lines (IC50s = 22.5-51.8 μM). It enhances cytotoxicity induced by bortezomib in HL-60 cells, as well as cytotoxicity induced by epirubicin or daunorubicin in CCRF-HSB-2 T cell acute lymphoblastic leukemia cells.

Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) is an inducer of ferroptosis.1 It induces ferroptosis, but not apoptosis or necroptosis, in NB1 cancer cells when used at a concentration of 3 μM.1 Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) inhibits proliferation of BJAB, NALM-6, Jurkat, MelHO, and MCF-7 cancer cells (IC50s = 0.07, 2.5, 1.5, 3, and 5 μM, respectively), as well as NALM-6 cells resistant to daunorubicin and vincristine when used at concentrations ranging from 0.04 to 0.125 μM.2 |1. Sagasser, J., Ma, B., Baecker, D., et al. A new approach in cancer treatment: Discovery of chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) complexes as ferroptosis inducers. J. Med. Chem. 62(17), 8053-8061 (2019).|2. Lee, S.-Y., Hille, A., Kitanovic, I., et al. [FeIII(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells. Leuk. Res. 35(3), 387-393 (2011).